Single-dose SARS-CoV-2 vaccination efficacy in the elderly
- PMID: 34174192
- PMCID: PMC8221733
- DOI: 10.1016/S1473-3099(21)00354-6
Single-dose SARS-CoV-2 vaccination efficacy in the elderly
Conflict of interest statement
We declare no competing interests.
Comment on
-
Effectiveness of BNT162b2 and ChAdOx1 nCoV-19 COVID-19 vaccination at preventing hospitalisations in people aged at least 80 years: a test-negative, case-control study.Lancet Infect Dis. 2021 Nov;21(11):1539-1548. doi: 10.1016/S1473-3099(21)00330-3. Epub 2021 Jun 23. Lancet Infect Dis. 2021. PMID: 34174190 Free PMC article.
-
Vaccine effectiveness of the first dose of ChAdOx1 nCoV-19 and BNT162b2 against SARS-CoV-2 infection in residents of long-term care facilities in England (VIVALDI): a prospective cohort study.Lancet Infect Dis. 2021 Nov;21(11):1529-1538. doi: 10.1016/S1473-3099(21)00289-9. Epub 2021 Jun 23. Lancet Infect Dis. 2021. PMID: 34174193 Free PMC article.
References
-
- Department of Health and Social Care Optimising the COVID-19 vaccination programme for maximum short-term impact. Jan 26, 2021. https://www.gov.uk/government/publications/prioritising-the-first-covid-...
-
- Hyams C, Marlow R, Maseko Z, et al. Effectiveness of BNT162b2 and 1 ChAdOx1n CoV-19 COVID19 vaccination at preventing hospitalisations in people aged at least 80 years: a test-negative, case-control study. Lancet Infect Dis. 2021 doi: 10.1016/S1473-3099(21)00330-3. published online June 23. - DOI - PMC - PubMed
-
- Shrotri M, Krutikov M, Palmer T, et al. Vaccine effectiveness of the first dose of ChAdOx1 nCoV-19 and BNT162b2 against SARS-CoV-2 infection in residents of long-term care facilities in England (VIVALDI): a prospective cohort study. Lancet Infect Dis. 2021 doi: 10.1016/S1473-3099(21)00289-9. published online June 23. - DOI - PMC - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous
